{"ts_utc": "2025-11-05T20:03:32.802807+00:00", "question": "What inflammatory biomarkers are linked to endometriosis?", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 3207, "usage": {"total_tokens": 568, "prompt_tokens": 356, "completion_tokens": 212}, "answer": "Several inflammatory biomarkers have been linked to endometriosis, as indicated by various studies:\n\n1. **Cytokines**: These are key players in the inflammatory response associated with endometriosis. Specific cytokines may be elevated in patients with the condition, contributing to the inflammatory environment.\n\n2. **Serum-based inflammatory markers**: A case-control study evaluated various serum inflammatory and hematological markers, suggesting that certain markers could be indicative of endometriosis.\n\n3. **Anti-Müllerian Hormone (AMH)**: This hormone, while primarily associated with ovarian reserve, has been investigated alongside inflammatory markers to assess systemic inflammation's impact on ovarian function in endometriosis patients.\n\n4. **Proteomic analysis**: Research is ongoing to identify proteins with significantly different levels in peritoneal fluid, serum, and uterine fluid from women with endometriosis compared to controls, which may include inflammatory biomarkers.\n\nThese findings highlight the complex interplay between inflammation and endometriosis, suggesting that monitoring these biomarkers could aid in understanding and managing the disease.", "docs": [{"rank": 1, "uid": "e4563e41d48356944f5d7e7fda6455a67488a71ed149ea666c319702045ffaa5", "score": 0.5258806347846985, "title": "Circulating inflammatory biomarkers and endometriosis lesion characteristics in the WisE consortium.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41180139/"}, {"rank": 2, "uid": "a2d85fd3cf0821079c54cdcd52b2b46bb14c520767908801bba39be6e39efc29", "score": 0.6048921346664429, "title": "Is systemic inflammation associated with reduced ovarian reserve in endometriosis? An investigation of anti-Müllerian hormone and inflammatory markers.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41133913/"}, {"rank": 3, "uid": "35d6ba81e758aa03b9dd4973335f9bc5cd86b5438f7bcdcb566610fdb699190b", "score": 0.625739336013794, "title": "Role of cytokines in endometriosis", "source": "openalex", "url": "https://doi.org/10.1016/s0015-0282(01)01816-7"}, {"rank": 4, "uid": "ec29de882f89600d5898c956e7da19785c9a27ac276c34c8a2e130bd2347dcdd", "score": 0.650098443031311, "title": "Evaluation of serum-based inflammatory and haematological markers in patients with endometriosis: A case-control study.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41045781/"}, {"rank": 5, "uid": "2748a56c52883c3600b77dbd1504f8c4f215cd175e901bf691b61b67b6303046", "score": 0.650479793548584, "title": "Biomarkers in Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04591548"}], "query_id": 1}
{"ts_utc": "2025-11-05T20:14:26.899851+00:00", "question": "What inflammatory biomarkers are linked to endometriosis?", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 3267, "usage": {"total_tokens": 551, "prompt_tokens": 356, "completion_tokens": 195}, "answer": "Several inflammatory biomarkers have been linked to endometriosis, including:\n\n1. **Cytokines**: Various studies indicate that cytokines play a significant role in the pathophysiology of endometriosis, contributing to inflammation and lesion development.\n\n2. **Serum-based inflammatory markers**: Research has evaluated specific inflammatory and hematological markers in patients with endometriosis, suggesting alterations in these biomarkers compared to controls.\n\n3. **Anti-Müllerian hormone (AMH)**: While primarily a marker of ovarian reserve, studies have investigated its association with systemic inflammation in endometriosis, indicating potential links to inflammatory processes.\n\n4. **Proteomic analysis**: Ongoing research aims to identify proteins with altered levels in peritoneal fluid, serum, and uterine fluid of women with endometriosis, which may serve as additional inflammatory biomarkers.\n\nThese findings highlight the complex interplay between inflammation and endometriosis, but further research is needed to establish definitive biomarkers.", "docs": [{"rank": 1, "uid": "e4563e41d48356944f5d7e7fda6455a67488a71ed149ea666c319702045ffaa5", "score": 0.5258806347846985, "title": "Circulating inflammatory biomarkers and endometriosis lesion characteristics in the WisE consortium.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41180139/"}, {"rank": 2, "uid": "a2d85fd3cf0821079c54cdcd52b2b46bb14c520767908801bba39be6e39efc29", "score": 0.6048921346664429, "title": "Is systemic inflammation associated with reduced ovarian reserve in endometriosis? An investigation of anti-Müllerian hormone and inflammatory markers.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41133913/"}, {"rank": 3, "uid": "35d6ba81e758aa03b9dd4973335f9bc5cd86b5438f7bcdcb566610fdb699190b", "score": 0.625739336013794, "title": "Role of cytokines in endometriosis", "source": "openalex", "url": "https://doi.org/10.1016/s0015-0282(01)01816-7"}, {"rank": 4, "uid": "ec29de882f89600d5898c956e7da19785c9a27ac276c34c8a2e130bd2347dcdd", "score": 0.650098443031311, "title": "Evaluation of serum-based inflammatory and haematological markers in patients with endometriosis: A case-control study.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41045781/"}, {"rank": 5, "uid": "2748a56c52883c3600b77dbd1504f8c4f215cd175e901bf691b61b67b6303046", "score": 0.650479793548584, "title": "Biomarkers in Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04591548"}], "query_id": 2}
{"ts_utc": "2025-11-05T21:13:28.133667+00:00", "question": "What are the biggest insights in endometriosis over the past month? Today's date is 11/5/95", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 1624, "usage": {"total_tokens": 565}, "answer": "I'm uncertain about the biggest insights in endometriosis over the past month, as the provided context does not include any recent updates or findings specific to that timeframe. The information available discusses the general state of knowledge, challenges in diagnosis and treatment, and the need for increased research funding, but does not provide recent insights or developments.", "docs": [{"rank": 1, "uid": "acc757e7c94e9cd87fea635cbd950f22aafe0d53a56df076d5eff119f1499c77", "score": 0.8472964763641357, "title": "News from the Endometriosis Movement", "source": "crossref", "url": "https://doi.org/10.1177/228402651000200209"}, {"rank": 2, "uid": "c67c16d3b4f8edb4f222cb98e3fe14fabbb7e0085a34f85b1d4da8c12067861b", "score": 0.8895808458328247, "title": "The history of endometriosis", "source": "crossref", "url": "https://doi.org/10.1201/b14621-6"}, {"rank": 3, "uid": "b2a93d91e66b26b7d8695c24aad259aad5cc55ac41b0d7e9b5981c44f9b209b7", "score": 0.9135591983795166, "title": "Endometriosis Is Undervalued: A Call to Action", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/51b1018eb1955051329c6803d627b9cc2dabcf08"}, {"rank": 4, "uid": "292bab17f742c860b79059d71953479b91f48dce976ea3ae073885dd250650b4", "score": 0.9137287139892578, "title": "Endometriosis: Evolution", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11879_1"}, {"rank": 5, "uid": "aa95f21f6ee87ca335bcc69ac5c46e957409175a622117a94333ea3bc2d945dc", "score": 0.938410758972168, "title": "Basic science of endometriosis", "source": "crossref", "url": "https://doi.org/10.3109/9781439804766-2"}], "query_id": 3}
{"ts_utc": "2025-11-05T21:14:18.161196+00:00", "question": "What is the most popular treatment for endometriosis?", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 768, "usage": {"total_tokens": 292}, "answer": "The provided context does not specify the most popular treatment for endometriosis. Therefore, I cannot determine the answer based on the information given.", "docs": [{"rank": 1, "uid": "d6258d54edfbbffc5978f149742f927a88dad58c910f8dedfdbb90d223a766ce", "score": 0.6577582955360413, "title": "Laparoscopic surgery for endometriosis.", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/703ff3236e2874db969de2aa756b2d50f4c833e8"}, {"rank": 2, "uid": "79057ad166b07b71cd1bea29bb1276d7f5743540aaeb855f8b21bfc82be1eb5d", "score": 0.6761354207992554, "title": "Consensus on current management of endometriosis", "source": "openalex", "url": "https://doi.org/10.1093/humrep/det050"}, {"rank": 3, "uid": "6e14d0c983b0b70e9e26eb83c2a2afa035308d7f2a68a2976d688b62df4555b3", "score": 0.6800035238265991, "title": "Medical Therapy of Endometriosis", "source": "crossref", "url": "https://doi.org/10.4324/9780203319390_chapter_14"}, {"rank": 4, "uid": "0b90375ef948eb77f3e0ea499061d700e6d4887de9a491766ceb9b4fa66ac3db", "score": 0.6802128553390503, "title": "Medical Therapy of Endometriosis", "source": "crossref", "url": "https://doi.org/10.3109/9780203319390-21"}, {"rank": 5, "uid": "ca1932ee0c185d53f283dad29bcb58b6162cb6dd4b9b997a7c0c220f71380b66", "score": 0.6836709976196289, "title": "Clinical Management of Endometriosis", "source": "openalex", "url": "https://doi.org/10.1097/aog.0000000000002469"}], "query_id": 4}
{"ts_utc": "2025-11-05T21:14:48.450069+00:00", "question": " What inflammatory biomarkers are linked to endometriosis?", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 1778, "usage": {"total_tokens": 418}, "answer": "The provided context does not specify particular inflammatory biomarkers linked to endometriosis. However, it mentions studies related to circulating inflammatory biomarkers, systemic inflammation, and the role of cytokines in endometriosis, which suggests that various inflammatory markers may be investigated in relation to the condition. For specific biomarkers, further details from the studies would be needed.", "docs": [{"rank": 1, "uid": "e4563e41d48356944f5d7e7fda6455a67488a71ed149ea666c319702045ffaa5", "score": 0.5258806347846985, "title": "Circulating inflammatory biomarkers and endometriosis lesion characteristics in the WisE consortium.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41180139/"}, {"rank": 2, "uid": "a2d85fd3cf0821079c54cdcd52b2b46bb14c520767908801bba39be6e39efc29", "score": 0.6048921346664429, "title": "Is systemic inflammation associated with reduced ovarian reserve in endometriosis? An investigation of anti-Müllerian hormone and inflammatory markers.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41133913/"}, {"rank": 3, "uid": "35d6ba81e758aa03b9dd4973335f9bc5cd86b5438f7bcdcb566610fdb699190b", "score": 0.625739336013794, "title": "Role of cytokines in endometriosis", "source": "openalex", "url": "https://doi.org/10.1016/s0015-0282(01)01816-7"}, {"rank": 4, "uid": "ec29de882f89600d5898c956e7da19785c9a27ac276c34c8a2e130bd2347dcdd", "score": 0.650098443031311, "title": "Evaluation of serum-based inflammatory and haematological markers in patients with endometriosis: A case-control study.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41045781/"}, {"rank": 5, "uid": "2748a56c52883c3600b77dbd1504f8c4f215cd175e901bf691b61b67b6303046", "score": 0.650479793548584, "title": "Biomarkers in Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04591548"}], "query_id": 5}
{"ts_utc": "2025-11-05T21:26:11.409644+00:00", "question": "Provide the top 5 topics", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 1267, "usage": {"total_tokens": 340}, "answer": "The top 5 topics based on the provided context are:\n\n1. Ectopic pregnancy research priorities\n2. Menstruation experiences and needs on social media\n3. Classification and statistical methods in acupuncture for endometriosis\n4. Research trends in minimally invasive gynecologic surgery\n5. Women's reproductive mental health and multimodal large language models", "docs": [{"rank": 1, "uid": "eb78858a40e60041bfc4f83bfefccf682434d573bde257ff9573d7088bbd4c91", "score": 1.3544005155563354, "title": "Top 10 priorities for future ectopic pregnancy research: an international consensus development study.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41022167/"}, {"rank": 2, "uid": "3070cd36eae2765a8de99c3e320c2e296cfc7138cbb98d5dc902127869aa7220", "score": 1.4962267875671387, "title": "Large Language Models Reveal Menstruation Experiences and Needs on Social Media.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/40775958/"}, {"rank": 3, "uid": "38a27f57289b9dd1443c33a8e2134f615e17a853561c7227aea3288a166e82e1", "score": 1.536030650138855, "title": "Concerns on classification, statistical methods, and interpretation in NMA on acupuncture for endometriosis.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41145739/"}, {"rank": 4, "uid": "c2d763ba801db9a41dc8ede94108cb4ece79ae5531d94d4cd2f2d2bccb2ed5e6", "score": 1.5408086776733398, "title": "Research Trends and Hotspots in Minimally Invasive Gynecologic Surgery: A Bibliometric and Visualization Analysis.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41040842/"}, {"rank": 5, "uid": "b5b5bc63e1e1b1d4bea239fbd1a3ff90553cab890679417a828cc1c37038a84c", "score": 1.5548615455627441, "title": "Multimodal large language models for women's reproductive mental health.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41148324/"}], "query_id": 6}
{"ts_utc": "2025-11-05T21:26:37.808835+00:00", "question": "summarize the top 5 topics with a paragraph each", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 4437, "usage": {"total_tokens": 1266}, "answer": "1. **Ectopic Pregnancy Research Priorities**: The study outlines the top ten priorities for future research on ectopic pregnancy, emphasizing the need for a consensus among international experts. Key areas of focus include improving diagnostic methods, understanding the underlying mechanisms of ectopic pregnancies, and developing effective treatment protocols. The consensus aims to guide researchers and healthcare professionals in addressing the significant gaps in knowledge and improving patient outcomes related to ectopic pregnancies.\n\n2. **Minimally Invasive Gynecologic Surgery Trends**: This bibliometric analysis investigates the current trends and hotspots in minimally invasive gynecologic surgery. It highlights the increasing interest in this field, driven by advancements in technology and techniques that enhance patient recovery and reduce complications. The study provides insights into the most cited research articles, emerging technologies, and future directions for research, indicating a growing emphasis on patient-centered approaches and innovative surgical methods.\n\n3. **Nursing Education and Women's Health Literacy**: The discussion focuses on the impact of nursing education interventions on women's health literacy regarding plasticizers, particularly phthalates. These environmental hormones are linked to various health issues, including infertility and endometriosis. The study underscores the importance of educating healthcare providers to improve women's understanding of the risks associated with plasticizers, ultimately aiming to enhance health outcomes and promote informed decision-making among women.\n\n4. **Acupuncture for Endometriosis**: This article raises concerns about the classification, statistical methods, and interpretation of network meta-analyses (NMA) related to acupuncture treatments for endometriosis. It critiques the existing methodologies and calls for more rigorous standards in research to ensure reliable conclusions. The discussion highlights the need for improved research designs that can accurately assess the efficacy of acupuncture as a treatment option for endometriosis, addressing the complexities of this condition.\n\n5. **Kaggle Challenge in Cryo-Electron Tomography**: The Kaggle challenge aimed at improving particle picking in cryo-electron tomography showcased the potential of machine learning in this field. Over 1000 participants contributed to developing algorithms that surpassed existing methods. The challenge emphasized the importance of data augmentation and robust annotation quality measures. The results and resources generated from this competition are expected to facilitate further advancements in cryo-electron tomography, enhancing the accuracy of molecular structure determination.", "docs": [{"rank": 1, "uid": "eb78858a40e60041bfc4f83bfefccf682434d573bde257ff9573d7088bbd4c91", "score": 1.4875962734222412, "title": "Top 10 priorities for future ectopic pregnancy research: an international consensus development study.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41022167/"}, {"rank": 2, "uid": "c2d763ba801db9a41dc8ede94108cb4ece79ae5531d94d4cd2f2d2bccb2ed5e6", "score": 1.549931526184082, "title": "Research Trends and Hotspots in Minimally Invasive Gynecologic Surgery: A Bibliometric and Visualization Analysis.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41040842/"}, {"rank": 3, "uid": "f3335718857ca861c919e8d5469f01c110fcbbfca99cde5d238b696827a716df", "score": 1.5561976432800293, "title": "Discussion on the Effect of Nursing Education Intervention on Women's Health Literacy of Plasticizers", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05024227"}, {"rank": 4, "uid": "38a27f57289b9dd1443c33a8e2134f615e17a853561c7227aea3288a166e82e1", "score": 1.5723809003829956, "title": "Concerns on classification, statistical methods, and interpretation in NMA on acupuncture for endometriosis.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41145739/"}, {"rank": 5, "uid": "d5d94d775b6749d35a43f5b61780639b58da77394f8b7d2f6ea31aa166d53cbf", "score": 1.572985291481018, "title": "Lessons learned from a Kaggle challenge for particle picking in cryo-electron tomography", "source": "biorxiv", "url": "https://www.biorxiv.org/content/10.1101/2025.11.03.686153v1?rss=1"}], "query_id": 7}
{"ts_utc": "2025-11-06T20:42:28.120701+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states?", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 5750, "usage": {"total_tokens": 1322}, "answer": "The latest insights into treating endometriosis emphasize the role of hormonal treatments, which are primarily aimed at managing the disease's chronic nature and its associated symptoms, such as menstrual pain and infertility. These treatments focus on blocking menstruation by inhibiting the hypothalamus-pituitary-ovary axis or inducing a state of pseudodecidualization, leading to amenorrhea and potentially slowing the progression of endometriotic implants. GnRH agonists and antagonists are highlighted as effective options in this regard.\n\nAdditionally, there is a growing understanding of the immune microenvironment's role in endometriosis. The interaction between immune factors and hormonal changes contributes to the disease's pathogenesis, suggesting that treatments could also target immune responses alongside hormonal therapies. This is particularly relevant given the systemic comorbidities associated with endometriosis, such as autoimmune diseases and mental health disorders, which may be influenced by the chronic inflammation and hormonal dysregulation seen in endometriosis patients.\n\nFurthermore, the complexity of endometriosis-associated infertility is acknowledged, with a multifactorial approach needed for treatment. The heterogeneity among patients means that tailored treatments based on individual clinical presentations are essential. Innovative diagnostic tools are being developed to better identify specific dysfunctions in the reproductive process related to endometriosis, which could lead to more effective and personalized treatment strategies.\n\nOverall, the insights suggest a need for an integrated approach that considers hormonal, immune, and systemic factors in the management of endometriosis, potentially improving outcomes for affected women.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.6776442527770996, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.7143514752388, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 3, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.7159315347671509, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 4, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7212878465652466, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 5, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7238348722457886, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}], "query_id": 8}
{"ts_utc": "2025-11-07T13:01:40.213630+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other diseases", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 3170, "usage": {"total_tokens": 1037}, "answer": "The latest insights into treating endometriosis highlight the importance of hormonal treatments, which are primarily aimed at managing the disease's endocrine aspects. These treatments focus on blocking menstruation by inhibiting the hypothalamus-pituitary-ovary axis or inducing a state of pseudodecidualization, leading to amenorrhea and potentially slowing the progression of endometriotic implants. GnRH agonists and antagonists have been noted as effective options in this regard.\n\nMoreover, the understanding of endometriosis as a chronic systemic disease has expanded, revealing its connections to various comorbidities, including autoimmune disorders (like thyroiditis and arthritis), inflammatory conditions (such as gastrointestinal and urinary diseases), and mental health issues. This systemic perspective underscores the need for a comprehensive approach to treatment that considers these associated conditions.\n\nAdditionally, the complexity of endometriosis-associated infertility is acknowledged, with factors such as pain, inflammation, altered pelvic anatomy, and disrupted ovarian function playing significant roles. The heterogeneity of patients with endometriosis complicates diagnosis and treatment, suggesting that individualized management strategies are crucial. Innovative non-invasive diagnostic tools are being developed to better target specific reproductive dysfunctions related to endometriosis.\n\nIn summary, the treatment of endometriosis is evolving to incorporate a more holistic view of the disease, recognizing its systemic nature and the interplay with other health conditions, which may lead to more tailored and effective management strategies.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.7111130356788635, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.712361216545105, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 3, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7281334400177002, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}, {"rank": 4, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7374995946884155, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 5, "uid": "aa95f21f6ee87ca335bcc69ac5c46e957409175a622117a94333ea3bc2d945dc", "score": 0.7412450313568115, "title": "Basic science of endometriosis", "source": "crossref", "url": "https://doi.org/10.3109/9781439804766-2"}], "query_id": 9}
{"ts_utc": "2025-11-07T13:08:38.774115+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states?", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 10385, "usage": {"total_tokens": 1276}, "answer": "Recent insights into treating endometriosis highlight the importance of hormonal therapies, which are the most commonly used medical treatments. These therapies aim to manage the disease by blocking menstruation and inhibiting the hypothalamus-pituitary-ovary axis, leading to amenorrhea and potentially slowing the progression of endometriotic implants. Key hormonal treatments include GnRH agonists and antagonists, which have shown effectiveness in managing symptoms.\n\nAdditionally, the understanding of endometriosis as a chronic inflammatory disease has expanded, emphasizing the role of the immune microenvironment in its pathogenesis. Immune cells and inflammatory mediators contribute to the development of endometriotic lesions, suggesting that targeting the immune response may offer new therapeutic avenues.\n\nEndometriosis is also associated with various systemic comorbidities, including autoimmune disorders and mental health issues. This connection underscores the need for a holistic approach to treatment that considers these comorbidities and the multifactorial nature of the disease. The complexity of endometriosis, particularly its impact on fertility, necessitates individualized treatment strategies tailored to the specific clinical situation of each patient.\n\nOverall, the latest insights suggest a multifaceted approach to treating endometriosis, integrating hormonal management, immune modulation, and consideration of associated comorbidities to improve patient outcomes.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.6776442527770996, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.7143514752388, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 3, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.7159315347671509, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 4, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7212878465652466, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 5, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7238348722457886, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}], "query_id": 10}
{"ts_utc": "2025-11-07T13:08:59.666617+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states?", "top_k": 8, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 9049, "usage": {"total_tokens": 1897}, "answer": "Recent insights into treating endometriosis highlight the importance of understanding its complex pathophysiology, which includes hormonal, immune, and inflammatory components. Hormonal treatments, particularly those targeting the hypothalamus-pituitary-ovary axis, remain the most common approach. These treatments aim to induce amenorrhea and inhibit the progression of endometriotic lesions. GnRH agonists and antagonists have shown effectiveness in this regard.\n\nMoreover, the role of the immune microenvironment in endometriosis is gaining attention. Immune cells and inflammatory mediators contribute to the development and persistence of endometriotic lesions, suggesting that therapies targeting the immune response could be beneficial. This is particularly relevant given the systemic comorbidities associated with endometriosis, such as autoimmune disorders and mental health issues, which may be influenced by the chronic inflammatory state of the disease.\n\nAdditionally, the recognition of endometriosis as a multifactorial systemic disease underscores the need for tailored treatment approaches. The heterogeneity of endometriosis-related infertility, influenced by factors like pelvic anatomy and ovarian function, calls for individualized management strategies. Innovative diagnostic tools are being developed to better understand and target specific dysfunctions in the reproductive process.\n\nOverall, the latest insights suggest that a comprehensive approach, integrating hormonal treatments with immune modulation and personalized care, may improve outcomes for women with endometriosis while also addressing associated comorbidities.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.6776442527770996, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.7143514752388, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 3, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.7159315347671509, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 4, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7212878465652466, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 5, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7238348722457886, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}, {"rank": 6, "uid": "0947e9ceb6f1138722b211112ccd918e05934748a83ed32d9af87297a5a1d0f3", "score": 0.7291330695152283, "title": "\"Is the Reduced Quality of Life of Women With Endometriosis the Result of Peritoneal Dysbiosis?\"", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05824819"}, {"rank": 7, "uid": "b50608443e3bb58046c2144ee31552ebf0866d8d5891ec4a8462907ed108bb76", "score": 0.7323662042617798, "title": "Endometriosis.", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/65040787dce0d5e2c5ea1422c1499c9646f18963"}, {"rank": 8, "uid": "c0d9b1437dedf0d47b2bd55b268c0976994ea834c7e7568c23a15b83f3447f0a", "score": 0.7427862286567688, "title": "Molecular Pathogenesis of Ovarian Endometrioma: Mechanistic Insights and Therapeutic Implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41045128/"}], "query_id": 11}
{"ts_utc": "2025-11-07T17:57:16.754290+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 3363, "usage": {"total_tokens": 1036}, "answer": "The latest insights into treating endometriosis emphasize the importance of hormonal treatments, which are the most commonly used medical interventions. These treatments are based on the understanding of the endocrine aspects of the disease, particularly the estrogen-dependency and progesterone-resistance that contribute to the ectopic implantation of endometrial cells. This hormonal approach aims to inhibit menstruation and induce a state of amenorrhea, thereby impeding the progression of endometriotic implants.\n\nAdditionally, the research highlights the systemic nature of endometriosis, linking it to various comorbidities such as autoimmune disorders (e.g., thyroiditis, arthritis), inflammatory diseases (e.g., gastrointestinal and urinary issues), and mental health disorders. This systemic perspective suggests that managing endometriosis may also involve addressing these associated conditions.\n\nFurthermore, there is a recognition of the complexity of endometriosis-associated infertility, which is influenced by multiple factors including inflammation, altered pelvic anatomy, and compromised ovarian function. The heterogeneity of patients with endometriosis poses challenges for diagnosis and treatment, indicating a need for tailored approaches. Innovative non-invasive diagnostic tools are being developed to better target specific dysfunctions in the reproductive process, which could lead to more effective individualized treatments.\n\nOverall, the insights suggest that a comprehensive understanding of the endocrine mechanisms and associated systemic effects of endometriosis is crucial for improving treatment strategies and addressing the multifaceted nature of the disease.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.7149826288223267, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.7196865081787109, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 3, "uid": "aa95f21f6ee87ca335bcc69ac5c46e957409175a622117a94333ea3bc2d945dc", "score": 0.7417842149734497, "title": "Basic science of endometriosis", "source": "crossref", "url": "https://doi.org/10.3109/9781439804766-2"}, {"rank": 4, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7433725595474243, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 5, "uid": "b0c661a17817a15fe106915bbdddfe7dffe71c9f74ca8a455c5688438d37921a", "score": 0.7441515922546387, "title": "Rethinking mechanisms, diagnosis and management of endometriosis", "source": "openalex", "url": "https://doi.org/10.1038/s41574-019-0245-z"}], "query_id": 12}
{"ts_utc": "2025-11-07T17:59:52.266811+00:00", "question": "Today is 11/7/2025. Is there anything new about biomarkers for diagnosis of endometriosis. ", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 4326, "usage": {"total_tokens": 1460}, "answer": "As of today, November 7, 2025, the latest information regarding biomarkers for the diagnosis of endometriosis includes ongoing research and clinical trials aimed at identifying and validating potential biomarkers. Here are some key points from the provided context:\n\n1. **Current Research**: There are several studies investigating various biomarkers associated with endometriosis. These studies aim to develop non-invasive diagnostic tools that could facilitate earlier detection of the disease, which is currently diagnosed primarily through invasive procedures like laparoscopy.\n\n2. **RNA-based Markers**: One study is focused on identifying mRNA markers that could serve as a non-invasive diagnostic tool for endometriosis. This research is in the discovery and validation phase, aiming to create a gene expression panel specific to endometriosis.\n\n3. **Galectin Research**: Another study is exploring the role of galectins (specifically Gal-1, Gal-3, and Gal-9) in the non-invasive diagnosis of endometriosis. Galectins are proteins that may play a role in immune regulation and could potentially serve as biomarkers for the disease.\n\n4. **Multicenter Nationwide Study**: A prospective study is being conducted to investigate blood and tissue markers for improving the diagnosis and prognosis of endometriosis. This study aims to correlate these biomarkers with clinical manifestations of the disease, including relapse and fertility issues.\n\nOverall, while significant progress is being made in the identification of biomarkers for endometriosis, the development of a reliable, non-invasive diagnostic test is still in progress, and results from ongoing studies will be crucial in determining their effectiveness.", "docs": [{"rank": 1, "uid": "9fa3a4f52283e04b2a2ec5bd030abc8b80c80de5749abebf31b3ee0e32bb81d8", "score": 0.7011004686355591, "title": "Potential biomarkers for early detection of endometriosis: current state of art (what we know so far).", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41081983/"}, {"rank": 2, "uid": "95344b12dff537d870bbad935b51359c3cd25d3bdb70b849efb0f476c37777ef", "score": 0.7017682790756226, "title": "Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. a Prospective Multicenter Nationwide Study. (ENDOBIO)", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05339451"}, {"rank": 3, "uid": "e11e37cea7a0807dea8d05a95ef6f00ee6141852ca19cb17e8f137f262d81e07", "score": 0.7160053253173828, "title": "Development and Evaluation of RNA-based Markers for Detecting and Diagnosing Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06907303"}, {"rank": 4, "uid": "4b5ed6a917c1ec5b3b49e427b207efbc86d797884388fc44ad1e0b34c97d1753", "score": 0.7762937545776367, "title": "Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01301885"}, {"rank": 5, "uid": "730a1a27bcbb8a9aaafc1f5e827ee5791aa866f60450eba92420762771c7ce34", "score": 0.7915133237838745, "title": "The Role of Galectin-1,3,9 in the the Non-invasive Diagnosis of Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04401592"}], "query_id": 13}
{"ts_utc": "2025-11-07T18:08:17.444512+00:00", "question": "List off endpoints used in recent clinical trials for endometriosis", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 3751, "usage": {"total_tokens": 859}, "answer": "Recent clinical trials for endometriosis have utilized various endpoints, including:\n\n1. **Efficacy** - Evaluating the effectiveness of treatments in reducing endometriosis-associated pain or symptoms.\n2. **Safety** - Assessing the safety profile of the treatments, including any adverse effects experienced by participants.\n3. **Tolerability** - Measuring how well patients can tolerate the treatment without significant side effects.\n4. **Clinical efficacy** - Specifically looking at the clinical outcomes related to the treatment's impact on endometriosis.\n5. **Pain assessment** - Focusing on the reduction of moderate to severe endometriosis-associated pain as a primary endpoint.\n\nThese endpoints are commonly reported in the summaries of the clinical trials mentioned.", "docs": [{"rank": 1, "uid": "8fedee547d04549d83a6969a4f89e701acf048d11a343750b5f568c424b85f9d", "score": 0.7418304681777954, "title": "GnRH Agonists in Endometriosis", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11879_9"}, {"rank": 2, "uid": "dbe23df553cdce98fe884b297ae2943e02ad92c72b8dac8a078b95af20a11cdd", "score": 0.7428377866744995, "title": "Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03481842"}, {"rank": 3, "uid": "070de75f14ca81dff37d7a394b2bab365e3c9fc232fe6d19688761fac6f9f91c", "score": 0.749549925327301, "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06963177"}, {"rank": 4, "uid": "cd830e6e9ec2a128419477aad0d8d78bc25ee2f734e346106a33bb57989ff40a", "score": 0.7595478892326355, "title": "A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(3)", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01629420"}, {"rank": 5, "uid": "af99bf4efe4ce53fd336fa88edfbd3f7e7d0d7c1671ebbaf68cc8d6e9e31b7ea", "score": 0.7694202661514282, "title": "A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05560646"}], "query_id": 14}
{"ts_utc": "2025-11-07T18:09:07.325634+00:00", "question": "List off endpoints used in recent clinical trials for endometriosis with specific measures", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 4251, "usage": {"total_tokens": 1098}, "answer": "Here are the endpoints used in recent clinical trials for endometriosis along with specific measures:\n\n1. **Vaginal Suppositories for Treatment of Endometriosis (NCT03481842)**\n   - Endpoints: Tolerability, safety, and clinical efficacy of vaginal suppository ELTA.\n\n2. **Specialized Nutraceutical for Endometriosis (NCT04091191)**\n   - Endpoints: Pain score and general well-being assessed using the EHP-30 questionnaire.\n\n3. **GenSci048 for Endometriosis-Associated Pain (NCT06963177)**\n   - Endpoints: Safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain.\n\n4. **OG-6219 for Endometriosis-related Pain (NCT05560646)**\n   - Endpoints: Efficacy, safety, and tolerability of three dose levels of OG-6219 in women with moderate to severe endometriosis-related pain.\n\n5. **HMI-115 for Endometriosis-Associated Pain (NCT05101317)**\n   - Endpoints: Safety and efficacy of HMI-115 compared to placebo over a 12-week treatment period for moderate to severe endometriosis-associated pain.", "docs": [{"rank": 1, "uid": "dbe23df553cdce98fe884b297ae2943e02ad92c72b8dac8a078b95af20a11cdd", "score": 0.730208158493042, "title": "Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03481842"}, {"rank": 2, "uid": "af35c3cdebd2ed3afe9f064bac0eac0f3a8f6ccbc9fa1398a0d6c7e9336b5e58", "score": 0.7514496445655823, "title": "A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04091191"}, {"rank": 3, "uid": "070de75f14ca81dff37d7a394b2bab365e3c9fc232fe6d19688761fac6f9f91c", "score": 0.7519226670265198, "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06963177"}, {"rank": 4, "uid": "af99bf4efe4ce53fd336fa88edfbd3f7e7d0d7c1671ebbaf68cc8d6e9e31b7ea", "score": 0.7576204538345337, "title": "A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05560646"}, {"rank": 5, "uid": "ff9d73bc223f8ee588d106c10579afc4923bb826eee93d61a59a1f4a04e5df31", "score": 0.7580350637435913, "title": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05101317"}], "query_id": 15}
{"ts_utc": "2025-11-07T18:10:10.998963+00:00", "question": "List off endpoints used in recent clinical trials for endometriosis with specific measures", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 8486, "usage": {"total_tokens": 1884}, "answer": "Here are the endpoints used in recent clinical trials for endometriosis along with specific measures:\n\n1. **Vaginal Suppositories for Treatment of Endometriosis (NCT03481842)**\n   - Endpoints: Tolerability, safety, and clinical efficacy of vaginal suppository ELTA.\n\n2. **Specialized Nutraceutical for Endometriosis (NCT04091191)**\n   - Endpoints: Pain score and general well-being assessed using the EHP-30 questionnaire.\n\n3. **GenSci048 for Endometriosis-Associated Pain (NCT06963177)**\n   - Endpoints: Safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain.\n\n4. **OG-6219 for Endometriosis-related Pain (NCT05560646)**\n   - Endpoints: Efficacy, safety, and tolerability of three dose levels of OG-6219 in women with moderate to severe endometriosis-related pain.\n\n5. **HMI-115 for Endometriosis-Associated Pain (NCT05101317)**\n   - Endpoints: Safety and efficacy of HMI-115 compared to placebo over a 12-week treatment period.\n\n6. **CCR1 Antagonist ZK 811752 (NCT00185341)**\n   - Endpoints: Safety, tolerability, and efficacy of ZK 811752 for endometriosis-associated pelvic pain over 12 weeks.\n\n7. **ERB-041 for Symptoms of Endometriosis (NCT00110487)**\n   - Endpoints: Safety and effectiveness in reducing symptoms associated with endometriosis, reduction in pain medication needs, and improvement in daily activities.\n\n8. **KLH-2109 for Endometriosis (NCT01629420)**\n   - Endpoints: Efficacy and safety of KLH-2109 in patients with endometriosis.\n\n9. **Laparoscopic Excision for Peritoneal Endometriosis (NCT05162794)**\n   - Endpoints: Effect on pelvic pain, quality of life, and neuropathic pain.\n\nThese endpoints focus on various aspects of treatment effectiveness, safety, tolerability, and quality of life improvements related to endometriosis.", "docs": [{"rank": 1, "uid": "dbe23df553cdce98fe884b297ae2943e02ad92c72b8dac8a078b95af20a11cdd", "score": 0.7300677299499512, "title": "Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03481842"}, {"rank": 2, "uid": "af35c3cdebd2ed3afe9f064bac0eac0f3a8f6ccbc9fa1398a0d6c7e9336b5e58", "score": 0.7513452172279358, "title": "A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04091191"}, {"rank": 3, "uid": "070de75f14ca81dff37d7a394b2bab365e3c9fc232fe6d19688761fac6f9f91c", "score": 0.7517998218536377, "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06963177"}, {"rank": 4, "uid": "af99bf4efe4ce53fd336fa88edfbd3f7e7d0d7c1671ebbaf68cc8d6e9e31b7ea", "score": 0.7574303150177002, "title": "A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05560646"}, {"rank": 5, "uid": "ff9d73bc223f8ee588d106c10579afc4923bb826eee93d61a59a1f4a04e5df31", "score": 0.7579402923583984, "title": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05101317"}, {"rank": 6, "uid": "ecaf9a06e0e429041c1a4e3ed972b3ce4f6b74b909a6047dca83d60d3f00d27f", "score": 0.7611140608787537, "title": "A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability and Efficacy of the CCR1 Antagonist ZK 811752, Given Orally in a Dose of 600 mg Three Times Daily, for the Treatment of Endometriosis Over 12 Weeks", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT00185341"}, {"rank": 7, "uid": "29a5cc994b9ba1240ef2b512b4359b9899dfed6a664ad6e0689b538a4995eb37", "score": 0.7658766508102417, "title": "A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Effect of ERB-041 in the Reduction of Symptoms Associated With Endometriosis in Reproductive-Age Women", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT00110487"}, {"rank": 8, "uid": "cd830e6e9ec2a128419477aad0d8d78bc25ee2f734e346106a33bb57989ff40a", "score": 0.768410325050354, "title": "A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(3)", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01629420"}, {"rank": 9, "uid": "e1774785625035336f6fde08620ff8aeaef159d8ee37552f67ad10bebc179c70", "score": 0.775604248046875, "title": "Is Laparoscopic Excision for Peritoneal Endometriosis Helpful or Harmful: A Double-blind, Randomized, Controlled, Three-armed Surgical Trial.", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05162794"}], "query_id": 16}
{"ts_utc": "2025-11-19T22:31:41.473241+00:00", "question": "Tell me the latest on endometriosis", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 1060, "usage": {"total_tokens": 278}, "answer": "I'm unable to provide the latest information on endometriosis as the context provided does not contain specific updates or findings. For the most current research and developments, I recommend checking the provided sources or other recent literature on the topic.", "docs": [{"rank": 1, "uid": "acc757e7c94e9cd87fea635cbd950f22aafe0d53a56df076d5eff119f1499c77", "score": 0.6508875489234924, "title": "News from the Endometriosis Movement", "source": "crossref", "url": "https://doi.org/10.1177/228402651000200209"}, {"rank": 2, "uid": "c67c16d3b4f8edb4f222cb98e3fe14fabbb7e0085a34f85b1d4da8c12067861b", "score": 0.7230783700942993, "title": "The history of endometriosis", "source": "crossref", "url": "https://doi.org/10.1201/b14621-6"}, {"rank": 3, "uid": "8e0b62817259a40ab0bd54a3b35778d339acac2c2512cc4afbd99cf1fac3214f", "score": 0.755037248134613, "title": "Endometriosis - a growing problem?", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/40923163/"}, {"rank": 4, "uid": "d127fa41d7bfe55c508dc35962492aacb9b2b694527b140390b12bd688c890ee", "score": 0.7566061615943909, "title": "The Pains of Endometriosis", "source": "openalex", "url": "https://doi.org/10.1126/science.1111445"}, {"rank": 5, "uid": "50eeafb7cedd16aca978fd035a5bbd1d3d036f4c5d249af52a7ae711d2ef6d15", "score": 0.7855558395385742, "title": "Endometriosis", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(04)17403-5"}], "query_id": 17}
{"ts_utc": "2025-11-19T22:32:08.716513+00:00", "question": "List off endpoints used in recent clinical trials for endometriosis with specific measures", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 4872, "usage": {"total_tokens": 1125}, "answer": "Here are the endpoints used in recent clinical trials for endometriosis along with specific measures:\n\n1. **Vaginal Suppositories for Treatment of Endometriosis (NCT03481842)**\n   - Endpoints: Tolerability, safety, and clinical efficacy of vaginal suppository ELTA.\n\n2. **Specialized Nutraceutical for Endometriosis (NCT04091191)**\n   - Endpoints: Pain score and general well-being assessed using the EHP-30 questionnaire.\n\n3. **GenSci048 for Endometriosis-Associated Pain (NCT06963177)**\n   - Endpoints: Safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain.\n\n4. **OG-6219 for Endometriosis-related Pain (NCT05560646)**\n   - Endpoints: Efficacy, safety, and tolerability of three dose levels of OG-6219 in women with moderate to severe endometriosis-related pain.\n\n5. **HMI-115 for Endometriosis-Associated Pain (NCT05101317)**\n   - Endpoints: Safety and efficacy of HMI-115 compared to placebo over a 12-week treatment period for subjects with moderate to severe endometriosis-associated pain. \n\nThese endpoints focus on various aspects of treatment effectiveness, safety, and patient-reported outcomes related to pain and well-being.", "docs": [{"rank": 1, "uid": "dbe23df553cdce98fe884b297ae2943e02ad92c72b8dac8a078b95af20a11cdd", "score": 0.7300677299499512, "title": "Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03481842"}, {"rank": 2, "uid": "af35c3cdebd2ed3afe9f064bac0eac0f3a8f6ccbc9fa1398a0d6c7e9336b5e58", "score": 0.7513452172279358, "title": "A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04091191"}, {"rank": 3, "uid": "070de75f14ca81dff37d7a394b2bab365e3c9fc232fe6d19688761fac6f9f91c", "score": 0.7517998218536377, "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06963177"}, {"rank": 4, "uid": "af99bf4efe4ce53fd336fa88edfbd3f7e7d0d7c1671ebbaf68cc8d6e9e31b7ea", "score": 0.7574303150177002, "title": "A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05560646"}, {"rank": 5, "uid": "ff9d73bc223f8ee588d106c10579afc4923bb826eee93d61a59a1f4a04e5df31", "score": 0.7579402923583984, "title": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05101317"}], "query_id": 18}
{"ts_utc": "2025-11-19T23:22:46.233962+00:00", "question": "List off endpoints used in recent clinical trials for endometriosis with specific measures", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 4267, "usage": {"total_tokens": 1122}, "answer": "Here are the endpoints used in recent clinical trials for endometriosis along with specific measures:\n\n1. **Vaginal Suppositories for Treatment of Endometriosis (NCT03481842)**\n   - Endpoints: Tolerability, safety, and clinical efficacy of vaginal suppository ELTA.\n\n2. **Specialized Nutraceutical for Endometriosis (NCT04091191)**\n   - Endpoints: Pain score and general well-being assessed using the EHP-30 questionnaire.\n\n3. **GenSci048 for Endometriosis-Associated Pain (NCT06963177)**\n   - Endpoints: Safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain.\n\n4. **OG-6219 for Endometriosis-related Pain (NCT05560646)**\n   - Endpoints: Efficacy, safety, and tolerability of three dose levels of OG-6219 in women with moderate to severe endometriosis-related pain.\n\n5. **HMI-115 for Endometriosis-Associated Pain (NCT05101317)**\n   - Endpoints: Safety and efficacy of HMI-115 compared to placebo over a 12-week treatment period for moderate to severe endometriosis-associated pain. \n\nThese endpoints focus on assessing the safety, efficacy, and tolerability of various treatments for endometriosis-related symptoms.", "docs": [{"rank": 1, "uid": "dbe23df553cdce98fe884b297ae2943e02ad92c72b8dac8a078b95af20a11cdd", "score": 0.7300677299499512, "title": "Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03481842"}, {"rank": 2, "uid": "af35c3cdebd2ed3afe9f064bac0eac0f3a8f6ccbc9fa1398a0d6c7e9336b5e58", "score": 0.7513452172279358, "title": "A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04091191"}, {"rank": 3, "uid": "070de75f14ca81dff37d7a394b2bab365e3c9fc232fe6d19688761fac6f9f91c", "score": 0.7517998218536377, "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06963177"}, {"rank": 4, "uid": "af99bf4efe4ce53fd336fa88edfbd3f7e7d0d7c1671ebbaf68cc8d6e9e31b7ea", "score": 0.7574303150177002, "title": "A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05560646"}, {"rank": 5, "uid": "ff9d73bc223f8ee588d106c10579afc4923bb826eee93d61a59a1f4a04e5df31", "score": 0.7579402923583984, "title": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05101317"}], "query_id": 19}
{"ts_utc": "2025-11-19T23:25:28.862336+00:00", "question": "List off endpoints used in recent clinical trials for endometriosis with specific measures", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 7068, "usage": {"total_tokens": 1877}, "answer": "Here are the endpoints used in recent clinical trials for endometriosis, along with specific measures:\n\n1. **Vaginal Suppositories for Treatment of Endometriosis (NCT03481842)**\n   - Endpoints: Tolerability, safety, and clinical efficacy of vaginal suppository ELTA.\n\n2. **Specialized Nutraceutical for Endometriosis (NCT04091191)**\n   - Endpoints: Pain score and general well-being assessed using the EHP-30 questionnaire.\n\n3. **GenSci048 for Endometriosis-Associated Pain (NCT06963177)**\n   - Endpoints: Safety and efficacy of GenSci048 in treating moderate to severe endometriosis-associated pain.\n\n4. **OG-6219 for Endometriosis-related Pain (NCT05560646)**\n   - Endpoints: Efficacy, safety, and tolerability of three dose levels of OG-6219 in women with moderate to severe endometriosis-related pain.\n\n5. **HMI-115 for Endometriosis-Associated Pain (NCT05101317)**\n   - Endpoints: Safety and efficacy of HMI-115 compared to placebo over a 12-week treatment period.\n\n6. **CCR1 Antagonist ZK 811752 (NCT00185341)**\n   - Endpoints: Safety, tolerability, and efficacy of ZK 811752 in treating endometriosis-associated pelvic pain over 12 weeks.\n\n7. **ERB-041 for Symptoms Associated with Endometriosis (NCT00110487)**\n   - Endpoints: Safety and effectiveness in reducing symptoms, reducing the need for pain medication, and improving daily activity capabilities.\n\n8. **Validation of Noninvasive Diagnostic Biomarkers for Endometriosis (NCT03161704)**\n   - Endpoints: Validation and optimization of genomic classifiers and serum markers as non-surgical markers of endometriosis.\n\n9. **KLH-2109 in Patients With Endometriosis (NCT01629420)**\n   - Endpoints: Efficacy and safety of KLH-2109 in patients with endometriosis.\n\nThese endpoints reflect a combination of safety, efficacy, tolerability, and symptom relief measures across various studies.", "docs": [{"rank": 1, "uid": "dbe23df553cdce98fe884b297ae2943e02ad92c72b8dac8a078b95af20a11cdd", "score": 0.7300677299499512, "title": "Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03481842"}, {"rank": 2, "uid": "af35c3cdebd2ed3afe9f064bac0eac0f3a8f6ccbc9fa1398a0d6c7e9336b5e58", "score": 0.7513452172279358, "title": "A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04091191"}, {"rank": 3, "uid": "070de75f14ca81dff37d7a394b2bab365e3c9fc232fe6d19688761fac6f9f91c", "score": 0.7517998218536377, "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06963177"}, {"rank": 4, "uid": "af99bf4efe4ce53fd336fa88edfbd3f7e7d0d7c1671ebbaf68cc8d6e9e31b7ea", "score": 0.7574303150177002, "title": "A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05560646"}, {"rank": 5, "uid": "ff9d73bc223f8ee588d106c10579afc4923bb826eee93d61a59a1f4a04e5df31", "score": 0.7579402923583984, "title": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05101317"}, {"rank": 6, "uid": "ecaf9a06e0e429041c1a4e3ed972b3ce4f6b74b909a6047dca83d60d3f00d27f", "score": 0.7611140608787537, "title": "A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability and Efficacy of the CCR1 Antagonist ZK 811752, Given Orally in a Dose of 600 mg Three Times Daily, for the Treatment of Endometriosis Over 12 Weeks", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT00185341"}, {"rank": 7, "uid": "29a5cc994b9ba1240ef2b512b4359b9899dfed6a664ad6e0689b538a4995eb37", "score": 0.7658766508102417, "title": "A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Effect of ERB-041 in the Reduction of Symptoms Associated With Endometriosis in Reproductive-Age Women", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT00110487"}, {"rank": 8, "uid": "dd38eab7bc3e30011db98a7adf766a17f0a414305a49fd28a8ddff1d9447c4ef", "score": 0.7683466076850891, "title": "Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03161704"}, {"rank": 9, "uid": "cd830e6e9ec2a128419477aad0d8d78bc25ee2f734e346106a33bb57989ff40a", "score": 0.768410325050354, "title": "A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(3)", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01629420"}], "query_id": 20}
{"ts_utc": "2025-11-19T23:26:14.361006+00:00", "question": "List off endpoints used in recent clinical trials for endometriosis with specific measures. Provide this in a table", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 7856, "usage": {"total_tokens": 2300}, "answer": "Here is a table listing the endpoints used in recent clinical trials for endometriosis along with specific measures:\n\n| Trial Title                                                                                                           | Endpoints                                                                                          | Specific Measures                                                                                       |\n|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|\n| Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis                      | Safety, tolerability, clinical efficacy                                                            | Patient-reported outcomes, adverse events, pain relief assessments                                     |\n| A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis | Pain score, general well-being                                                                      | EHP-30 questionnaire, pain score assessments                                                            |\n| A Phase 2a/b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of OG-6219   | Efficacy, safety, tolerability                                                                      | Pain assessments, adverse events, quality of life measures                                             |\n| A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 | Safety, efficacy                                                                                   | Pain relief assessments, adverse events, quality of life measures                                       |\n| A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Efficacy of ZK 811752 | Safety, tolerability, efficacy                                                                       | Pain assessments, adverse events, quality of life measures                                             |\n| A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives | Safety, efficacy                                                                                   | Dysmenorrhea response, pain assessments, quality of life measures                                       |\n| Is Laparoscopic Excision for Peritoneal Endometriosis Helpful or Harmful: A Double-blind, Randomized, Controlled Trial | Effect on pelvic pain, quality of life, neuropathic pain                                          | Pain assessments, quality of life questionnaires, neuropathic pain assessments                         |\n| A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess Efficacy and Safety of BAY 86-5300 | Efficacy, safety, bleeding pattern                                                                  | Pain assessments, adverse events, bleeding pattern evaluations                                          |\n| Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol          | Validation of noninvasive diagnostic biomarkers                                                     | Collection of biopsy tissue, serum, plasma, whole blood, urine; genomic classifiers and serum markers   |\n\nThis table summarizes the endpoints and specific measures utilized in various clinical trials related to endometriosis.", "docs": [{"rank": 1, "uid": "dbe23df553cdce98fe884b297ae2943e02ad92c72b8dac8a078b95af20a11cdd", "score": 0.8255876302719116, "title": "Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03481842"}, {"rank": 2, "uid": "af35c3cdebd2ed3afe9f064bac0eac0f3a8f6ccbc9fa1398a0d6c7e9336b5e58", "score": 0.8430995345115662, "title": "A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04091191"}, {"rank": 3, "uid": "af99bf4efe4ce53fd336fa88edfbd3f7e7d0d7c1671ebbaf68cc8d6e9e31b7ea", "score": 0.8498145341873169, "title": "A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05560646"}, {"rank": 4, "uid": "070de75f14ca81dff37d7a394b2bab365e3c9fc232fe6d19688761fac6f9f91c", "score": 0.8644157648086548, "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06963177"}, {"rank": 5, "uid": "ecaf9a06e0e429041c1a4e3ed972b3ce4f6b74b909a6047dca83d60d3f00d27f", "score": 0.865371823310852, "title": "A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability and Efficacy of the CCR1 Antagonist ZK 811752, Given Orally in a Dose of 600 mg Three Times Daily, for the Treatment of Endometriosis Over 12 Weeks", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT00185341"}, {"rank": 6, "uid": "5a6e6f27b77ea172be138e2d10e9568e3f0b557d463a6db794d08b9ca0e3f62a", "score": 0.8689146041870117, "title": "A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04333576"}, {"rank": 7, "uid": "e1774785625035336f6fde08620ff8aeaef159d8ee37552f67ad10bebc179c70", "score": 0.8704992532730103, "title": "Is Laparoscopic Excision for Peritoneal Endometriosis Helpful or Harmful: A Double-blind, Randomized, Controlled, Three-armed Surgical Trial.", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05162794"}, {"rank": 8, "uid": "644492c62e9823c6f25381ca57bbd91e5c969b53f4f8937e925556c4f5f5e3e2", "score": 0.8712513446807861, "title": "A Multi-center, Randomized, Double-blinded, Placebo-controlled, and Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of an Extended Flexible Regimen of BAY 86-5300 [0.02 mg Ethinylestradiol (β-CDC) and 3 mg Drospirenone] in the Patients With Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01697111"}, {"rank": 9, "uid": "dd38eab7bc3e30011db98a7adf766a17f0a414305a49fd28a8ddff1d9447c4ef", "score": 0.8747105598449707, "title": "Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03161704"}], "query_id": 21}
{"ts_utc": "2025-11-19T23:35:36.753657+00:00", "question": "What are some key new studies available for November 2025 in endometriosis?", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 1721, "usage": {"total_tokens": 1758}, "answer": "I'm sorry, but I cannot provide information on key new studies available for November 2025 in endometriosis, as the context provided does not include any studies or data from that time period. The studies mentioned are from various sources but do not specify their availability in November 2025.", "docs": [{"rank": 1, "uid": "4b5ed6a917c1ec5b3b49e427b207efbc86d797884388fc44ad1e0b34c97d1753", "score": 0.7206979990005493, "title": "Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01301885"}, {"rank": 2, "uid": "a38733645b7b573ff6e4f0402ad0ffa2e4580fb9e5be191cabf4a7c596d89ef3", "score": 0.7272486090660095, "title": "An Exploratory Study of Biomarkers in the Endometrial Fluid, Tissue, and Follicular Fluid of Moderate/Severe Endometriosis Patients: a Prospective Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT07182643"}, {"rank": 3, "uid": "a4b6e456a08e588ad1866dda46c56c8b850e020646f9e8a5451fa2b8a31d471d", "score": 0.78693687915802, "title": "EUmetriosis: Insights Into the Pathogenesis of Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT07000786"}, {"rank": 4, "uid": "95344b12dff537d870bbad935b51359c3cd25d3bdb70b849efb0f476c37777ef", "score": 0.789745032787323, "title": "Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. a Prospective Multicenter Nationwide Study. (ENDOBIO)", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05339451"}, {"rank": 5, "uid": "9fa3a4f52283e04b2a2ec5bd030abc8b80c80de5749abebf31b3ee0e32bb81d8", "score": 0.7914025187492371, "title": "Potential biomarkers for early detection of endometriosis: current state of art (what we know so far).", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41081983/"}, {"rank": 6, "uid": "caf1022ef3e49e740f27ba082f809ab73942361575931453ddbc241d8917e5d2", "score": 0.792737603187561, "title": "Infertility and Endometriosis : a Prospective Cohort Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01833013"}, {"rank": 7, "uid": "e11e37cea7a0807dea8d05a95ef6f00ee6141852ca19cb17e8f137f262d81e07", "score": 0.7928368449211121, "title": "Development and Evaluation of RNA-based Markers for Detecting and Diagnosing Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06907303"}, {"rank": 8, "uid": "30ce1aa96ae9f30a89a47568b1aaa7a1b4f57711a7a3902b3f640462cb1f9f8a", "score": 0.7928760051727295, "title": "Basic Sciences of Endometriosis", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11075_4"}, {"rank": 9, "uid": "4b1c5083cfb1104be43cb62c2ac690810b955caccd045eb987ba69bd4301942f", "score": 0.8002592325210571, "title": "A long-acting anti–IL-8 antibody improves inflammation and fibrosis in endometriosis", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/c25e8f76cc6c24109342b880b5ed5167515878da"}], "query_id": 22}
{"ts_utc": "2025-11-19T23:36:14.403543+00:00", "question": "What are some key new studies available for second half of 2025  in endometriosis?", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 1161, "usage": {"total_tokens": 1680}, "answer": "I'm unable to provide information on key new studies available for the second half of 2025 in endometriosis, as the context provided does not include any studies or data beyond the current date. If you have specific studies or areas of interest in mind, I can help summarize or provide information based on the context provided.", "docs": [{"rank": 1, "uid": "4b5ed6a917c1ec5b3b49e427b207efbc86d797884388fc44ad1e0b34c97d1753", "score": 0.7399793863296509, "title": "Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01301885"}, {"rank": 2, "uid": "a38733645b7b573ff6e4f0402ad0ffa2e4580fb9e5be191cabf4a7c596d89ef3", "score": 0.7505937814712524, "title": "An Exploratory Study of Biomarkers in the Endometrial Fluid, Tissue, and Follicular Fluid of Moderate/Severe Endometriosis Patients: a Prospective Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT07182643"}, {"rank": 3, "uid": "caf1022ef3e49e740f27ba082f809ab73942361575931453ddbc241d8917e5d2", "score": 0.7968056201934814, "title": "Infertility and Endometriosis : a Prospective Cohort Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT01833013"}, {"rank": 4, "uid": "30ce1aa96ae9f30a89a47568b1aaa7a1b4f57711a7a3902b3f640462cb1f9f8a", "score": 0.8024569153785706, "title": "Basic Sciences of Endometriosis", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11075_4"}, {"rank": 5, "uid": "9fa3a4f52283e04b2a2ec5bd030abc8b80c80de5749abebf31b3ee0e32bb81d8", "score": 0.8028011322021484, "title": "Potential biomarkers for early detection of endometriosis: current state of art (what we know so far).", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41081983/"}, {"rank": 6, "uid": "95344b12dff537d870bbad935b51359c3cd25d3bdb70b849efb0f476c37777ef", "score": 0.8048508763313293, "title": "Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. a Prospective Multicenter Nationwide Study. (ENDOBIO)", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05339451"}, {"rank": 7, "uid": "0bedad34a0e51de9b09480a4819ca3d408b098e7ce9c79f10b6fd016c7722844", "score": 0.8052904605865479, "title": "Next-Generation Endometriosis Diagnostics Through Comprehensive Multi-Dimensional Analysis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06572852"}, {"rank": 8, "uid": "76f47a0a117faf8898b5d3b143e1a946aed7ae387fb2b50e65d3b080cd4188bd", "score": 0.8085160255432129, "title": "Precision Therapeutic and Preventive Molecular Strategies for Endometriosis-Associated Infertility.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/40869026/"}, {"rank": 9, "uid": "e11e37cea7a0807dea8d05a95ef6f00ee6141852ca19cb17e8f137f262d81e07", "score": 0.8170127272605896, "title": "Development and Evaluation of RNA-based Markers for Detecting and Diagnosing Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06907303"}], "query_id": 23}
{"ts_utc": "2025-11-19T23:39:30.473626+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease staes", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 5807, "usage": {"total_tokens": 2120}, "answer": "Recent insights into treating endometriosis highlight its classification as a chronic systemic disease, which has implications for its management and understanding of associated comorbidities. Here are some key points regarding treatment and its relationship with other disease states:\n\n1. **Hormonal Treatments**: Hormonal therapies remain the cornerstone of medical treatment for endometriosis. These treatments aim to inhibit the hypothalamus-pituitary-ovary axis, leading to amenorrhea and reducing the progression of endometriotic lesions. GnRH agonists and antagonists are particularly noted for their effectiveness. The hormonal approach is based on the endocrine aspects of the disease, particularly the estrogen dependency and progesterone resistance observed in endometriotic tissues.\n\n2. **Systemic Comorbidities**: Endometriosis is associated with various systemic comorbidities, including autoimmune disorders (like thyroiditis and arthritis), inflammatory diseases (such as gastrointestinal and urinary conditions), and mental health issues. The interplay between hormonal changes and inflammation contributes to these comorbidities, suggesting that effective management of endometriosis may also alleviate associated systemic health issues.\n\n3. **Infertility and Tailored Treatments**: The relationship between endometriosis and infertility is complex and multifactorial. Factors such as altered pelvic anatomy, inflammation, and compromised ovarian function contribute to infertility in women with endometriosis. Innovative diagnostic tools are being developed to better understand these interactions and allow for more personalized treatment strategies.\n\n4. **Immune Microenvironment**: The immune system plays a significant role in the pathogenesis of endometriosis. The peritoneal immune microenvironment, influenced by hormonal factors, contributes to the development and persistence of endometriotic lesions. Understanding this relationship opens avenues for potential immunomodulatory therapies.\n\n5. **Microbiome Research**: Recent studies are exploring the role of the microbiome in endometriosis. The presence of specific microbial communities in the peritoneal cavity may correlate with disease severity and symptoms, suggesting that microbiome modulation could be a novel therapeutic approach.\n\nIn summary, the latest insights into treating endometriosis emphasize the need for a comprehensive understanding of its systemic nature and the interplay with other health conditions. This holistic view can guide more effective, individualized treatment strategies that address both the disease and its associated comorbidities.", "docs": [{"rank": 1, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.7112696170806885, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 2, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.7139657139778137, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 3, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7389428615570068, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}, {"rank": 4, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7406766414642334, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 5, "uid": "b50608443e3bb58046c2144ee31552ebf0866d8d5891ec4a8462907ed108bb76", "score": 0.7435799837112427, "title": "Endometriosis.", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/65040787dce0d5e2c5ea1422c1499c9646f18963"}, {"rank": 6, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.7436065077781677, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 7, "uid": "aa95f21f6ee87ca335bcc69ac5c46e957409175a622117a94333ea3bc2d945dc", "score": 0.745697557926178, "title": "Basic science of endometriosis", "source": "crossref", "url": "https://doi.org/10.3109/9781439804766-2"}, {"rank": 8, "uid": "0947e9ceb6f1138722b211112ccd918e05934748a83ed32d9af87297a5a1d0f3", "score": 0.7510238885879517, "title": "\"Is the Reduced Quality of Life of Women With Endometriosis the Result of Peritoneal Dysbiosis?\"", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05824819"}, {"rank": 9, "uid": "c0d9b1437dedf0d47b2bd55b268c0976994ea834c7e7568c23a15b83f3447f0a", "score": 0.751122772693634, "title": "Molecular Pathogenesis of Ovarian Endometrioma: Mechanistic Insights and Therapeutic Implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41045128/"}], "query_id": 24}
{"ts_utc": "2025-11-19T23:54:19.289005+00:00", "question": "Give me everything that has been FDA approved in endometriosis in the last 6 months. ", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 1840, "usage": {"total_tokens": 1487}, "answer": "The provided context does not contain specific information regarding any FDA approvals for endometriosis treatments in the last six months. Therefore, I cannot provide the requested details. If you have other sources or specific information, I may be able to assist further.", "docs": [{"rank": 1, "uid": "e3057c7123691d4b73a5a619e72b999ef6db21abf00e023244fff5a17b0f405e", "score": 0.9733285307884216, "title": "Using systems biology and drug repositioning approaches to discover FDA-approved drugs candidates for endometriosis treatment.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/40938862/"}, {"rank": 2, "uid": "8fedee547d04549d83a6969a4f89e701acf048d11a343750b5f568c424b85f9d", "score": 0.9887459874153137, "title": "GnRH Agonists in Endometriosis", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11879_9"}, {"rank": 3, "uid": "acc757e7c94e9cd87fea635cbd950f22aafe0d53a56df076d5eff119f1499c77", "score": 0.9888334274291992, "title": "News from the Endometriosis Movement", "source": "crossref", "url": "https://doi.org/10.1177/228402651000200209"}, {"rank": 4, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.9896334409713745, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 5, "uid": "904fba66b63c455bcfd89f8336e6b11939cc1a59df5571baaf23ca17e835a254", "score": 0.9909466505050659, "title": "Compliance With Medical Treatment for Endometriosis : a Cross-sectional Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05619757"}, {"rank": 6, "uid": "4b1c5083cfb1104be43cb62c2ac690810b955caccd045eb987ba69bd4301942f", "score": 1.0003507137298584, "title": "A long-acting anti–IL-8 antibody improves inflammation and fibrosis in endometriosis", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/c25e8f76cc6c24109342b880b5ed5167515878da"}, {"rank": 7, "uid": "dbe23df553cdce98fe884b297ae2943e02ad92c72b8dac8a078b95af20a11cdd", "score": 1.009130597114563, "title": "Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03481842"}, {"rank": 8, "uid": "e53efc48bf912647e7fc728a2dbc842e76f37c6f85c41f85b2d132582c151389", "score": 1.0125939846038818, "title": "Disparities in Racial and Ethnic Representation in Clinical Trials for FDA-Approved Treatments of Endometriosis.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/40928122/"}, {"rank": 9, "uid": "7d0fed0db86f950623e68827ea5347a23aff43670ae7f123bc5439d2dbcaabdc", "score": 1.0143147706985474, "title": "Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41194364/"}], "query_id": 25}
{"ts_utc": "2025-11-19T23:55:27.829693+00:00", "question": "I am a patient with endometriosis. I'm curious about related medications that can help me. Give me everything that has been FDA approved in endometriosis in the last 6 months. ", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 2005, "usage": {"total_tokens": 1587}, "answer": "I'm sorry, but the provided context does not include any specific information about medications that have been FDA approved for endometriosis in the last 6 months. The context discusses various treatments and ongoing studies but does not specify recent approvals. If you need the latest information on FDA approvals, I recommend checking the FDA's official website or consulting with a healthcare professional.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.7464881539344788, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "753210fe90cad422b60462b114c4590b9830ca793ea580e64eaa42c08a31da64", "score": 0.7822105884552002, "title": "Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03991520"}, {"rank": 3, "uid": "904fba66b63c455bcfd89f8336e6b11939cc1a59df5571baaf23ca17e835a254", "score": 0.7835763692855835, "title": "Compliance With Medical Treatment for Endometriosis : a Cross-sectional Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05619757"}, {"rank": 4, "uid": "274d3ff1fbfcbb3c908c84cf7c7d283e8a09871a9b4c20ae848b0d48fa7c0772", "score": 0.7915351390838623, "title": "Medical Management of Endometriosis", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11879_8"}, {"rank": 5, "uid": "8fedee547d04549d83a6969a4f89e701acf048d11a343750b5f568c424b85f9d", "score": 0.7962416410446167, "title": "GnRH Agonists in Endometriosis", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11879_9"}, {"rank": 6, "uid": "4b1c5083cfb1104be43cb62c2ac690810b955caccd045eb987ba69bd4301942f", "score": 0.8367562890052795, "title": "A long-acting anti–IL-8 antibody improves inflammation and fibrosis in endometriosis", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/c25e8f76cc6c24109342b880b5ed5167515878da"}, {"rank": 7, "uid": "6e14d0c983b0b70e9e26eb83c2a2afa035308d7f2a68a2976d688b62df4555b3", "score": 0.8392106294631958, "title": "Medical Therapy of Endometriosis", "source": "crossref", "url": "https://doi.org/10.4324/9780203319390_chapter_14"}, {"rank": 8, "uid": "0b90375ef948eb77f3e0ea499061d700e6d4887de9a491766ceb9b4fa66ac3db", "score": 0.8393032550811768, "title": "Medical Therapy of Endometriosis", "source": "crossref", "url": "https://doi.org/10.3109/9780203319390-21"}, {"rank": 9, "uid": "549fc5a0654dadfaafa376da2929f2d1c47787212b8791f0ed17ed77644daa13", "score": 0.843449056148529, "title": "Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04844996"}], "query_id": 26}
{"ts_utc": "2025-11-19T23:56:05.413280+00:00", "question": "I am a patient with endometriosis. I'm curious about related medications that can help me. Give me everything that has been FDA approved in endometriosis in the last 6 months. ", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 3231, "usage": {"total_tokens": 1599}, "answer": "I'm sorry, but the provided context does not include information about any FDA-approved medications for endometriosis in the last 6 months. The context mentions existing treatments such as GnRH agonists, GnRH antagonists, and other hormonal therapies, but it does not specify any recent approvals. If you need the latest updates on FDA approvals, I recommend checking the FDA's official website or consulting with a healthcare professional.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.7464881539344788, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "753210fe90cad422b60462b114c4590b9830ca793ea580e64eaa42c08a31da64", "score": 0.7822105884552002, "title": "Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03991520"}, {"rank": 3, "uid": "904fba66b63c455bcfd89f8336e6b11939cc1a59df5571baaf23ca17e835a254", "score": 0.7835763692855835, "title": "Compliance With Medical Treatment for Endometriosis : a Cross-sectional Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05619757"}, {"rank": 4, "uid": "274d3ff1fbfcbb3c908c84cf7c7d283e8a09871a9b4c20ae848b0d48fa7c0772", "score": 0.7915351390838623, "title": "Medical Management of Endometriosis", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11879_8"}, {"rank": 5, "uid": "8fedee547d04549d83a6969a4f89e701acf048d11a343750b5f568c424b85f9d", "score": 0.7962416410446167, "title": "GnRH Agonists in Endometriosis", "source": "crossref", "url": "https://doi.org/10.5005/jp/books/11879_9"}, {"rank": 6, "uid": "4b1c5083cfb1104be43cb62c2ac690810b955caccd045eb987ba69bd4301942f", "score": 0.8367562890052795, "title": "A long-acting anti–IL-8 antibody improves inflammation and fibrosis in endometriosis", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/c25e8f76cc6c24109342b880b5ed5167515878da"}, {"rank": 7, "uid": "6e14d0c983b0b70e9e26eb83c2a2afa035308d7f2a68a2976d688b62df4555b3", "score": 0.8392106294631958, "title": "Medical Therapy of Endometriosis", "source": "crossref", "url": "https://doi.org/10.4324/9780203319390_chapter_14"}, {"rank": 8, "uid": "0b90375ef948eb77f3e0ea499061d700e6d4887de9a491766ceb9b4fa66ac3db", "score": 0.8393032550811768, "title": "Medical Therapy of Endometriosis", "source": "crossref", "url": "https://doi.org/10.3109/9780203319390-21"}, {"rank": 9, "uid": "549fc5a0654dadfaafa376da2929f2d1c47787212b8791f0ed17ed77644daa13", "score": 0.843449056148529, "title": "Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04844996"}], "query_id": 27}
{"ts_utc": "2025-11-19T23:56:35.829627+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 2952, "usage": {"total_tokens": 1724}, "answer": "Recent insights into treating endometriosis highlight its classification as a chronic systemic disease, which necessitates a multifaceted approach to management. Hormonal treatments remain the cornerstone of medical therapy, focusing on blocking menstruation and addressing the endocrine aspects of the disease. This includes the use of GnRH agonists and antagonists, which effectively inhibit the hypothalamus-pituitary-ovary axis, leading to amenorrhea and potentially slowing the progression of endometriotic lesions.\n\nMoreover, the understanding of endometriosis has evolved to recognize its association with various comorbidities, including autoimmune disorders, inflammatory diseases, and mental health issues. The interplay between endometriosis and these conditions suggests that treatment strategies may need to be tailored not only to the endometriosis itself but also to the patient's overall health status and any concurrent diseases.\n\nInnovative diagnostic tools are being developed to better identify specific dysfunctions in the reproductive process associated with endometriosis, allowing for more personalized treatment plans. The role of the immune microenvironment in the pathogenesis of endometriosis is also gaining attention, with evidence indicating that immune factors contribute significantly to the disease's progression.\n\nIn summary, the latest insights into treating endometriosis emphasize a comprehensive approach that considers hormonal regulation, immune system interactions, and the management of associated comorbidities, aiming for individualized treatment strategies that address the complexity of this chronic condition.", "docs": [{"rank": 1, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.6951764225959778, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 2, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.6998381018638611, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 3, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7304941415786743, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 4, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7363815903663635, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}, {"rank": 5, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.736713707447052, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 6, "uid": "b50608443e3bb58046c2144ee31552ebf0866d8d5891ec4a8462907ed108bb76", "score": 0.7427248954772949, "title": "Endometriosis.", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/65040787dce0d5e2c5ea1422c1499c9646f18963"}, {"rank": 7, "uid": "aa95f21f6ee87ca335bcc69ac5c46e957409175a622117a94333ea3bc2d945dc", "score": 0.745269238948822, "title": "Basic science of endometriosis", "source": "crossref", "url": "https://doi.org/10.3109/9781439804766-2"}, {"rank": 8, "uid": "b0c661a17817a15fe106915bbdddfe7dffe71c9f74ca8a455c5688438d37921a", "score": 0.746875524520874, "title": "Rethinking mechanisms, diagnosis and management of endometriosis", "source": "openalex", "url": "https://doi.org/10.1038/s41574-019-0245-z"}, {"rank": 9, "uid": "9c1e885635e83e06dc84b9b8a2c72857049286ddc94e8c583f10eab32fbe02bd", "score": 0.746875524520874, "title": "Rethinking mechanisms, diagnosis and management of endometriosis", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/33762d90f39eaf1bb520c032ecaa85b017e3c9f1"}], "query_id": 28}
{"ts_utc": "2025-11-19T23:57:21.500229+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states. Provide the response in a table.", "top_k": 9, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 7512, "usage": {"total_tokens": 2876}, "answer": "Here are the latest insights regarding the treatment of endometriosis and their connections to other disease states, presented in a table format:\n\n| **Insight**                                                                 | **Description**                                                                                                                                                                                                                                   | **Connection to Other Disease States**                                                                                          |\n|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|\n| **Hormonal Treatments**                                                     | Hormonal drugs are the primary medical treatment for endometriosis, focusing on blocking menstruation and inhibiting the hypothalamus-pituitary-ovary axis. GnRH agonists and antagonists are effective.                                          | Hormonal treatments may influence autoimmune diseases and mental health disorders due to their systemic effects.               |\n| **Chronic Inflammatory Nature**                                             | Endometriosis is characterized as a chronic inflammatory disease, which can lead to systemic comorbidities such as autoimmune disorders (e.g., thyroiditis, arthritis) and gastrointestinal issues.                                             | The inflammatory nature of endometriosis may exacerbate conditions like autoimmune diseases and chronic pain syndromes.         |\n| **Nutritional Interventions**                                              | Dietary changes, such as reducing fat and increasing fiber, may help manage endometriosis symptoms by lowering estrogen levels. Plant-based diets with anti-inflammatory properties are beneficial.                                             | Nutrition can play a role in managing inflammation and may also impact other inflammatory conditions.                          |\n| **Individualized Treatment Approaches**                                     | Treatment should be tailored to the individual, considering the heterogeneity of endometriosis presentations and associated infertility challenges.                                                                                             | This individualized approach is crucial for managing comorbidities and optimizing reproductive health.                         |\n| **Emerging Non-invasive Diagnostic Tools**                                   | Innovative diagnostic tools are being developed to better identify dysfunctional reproductive processes in women with endometriosis, which may lead to more targeted treatments.                                                               | Improved diagnostics can enhance understanding of reproductive health and related conditions, potentially aiding fertility.     |\n| **Ezetimibe as a New Treatment**                                           | Ezetimibe, a cholesterol absorption inhibitor with anti-inflammatory properties, has shown promise in reducing endometriotic lesions in experimental models.                                                                                     | This treatment may have implications for metabolic health and inflammation, linking it to cardiovascular disease management.    |\n| **Impact of Immune Microenvironment**                                       | The immune microenvironment plays a significant role in the pathogenesis of endometriosis, with immune cells contributing to the disease's progression.                                                                                         | Dysregulation of immune responses can be linked to other autoimmune diseases and chronic inflammatory conditions.                |\n| **Surgical vs. Medical Management**                                         | Current recommendations suggest starting with hormonal suppressive treatment before considering surgery, reflecting a shift towards less invasive management strategies.                                                                          | Surgical interventions may be necessary for severe cases, which can also impact recovery and management of other health issues. |\n\nThis table summarizes the latest insights into endometriosis treatment and highlights how these insights relate to other health conditions.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.7493468523025513, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "1b2aa8d886c9548b81b94cf1bb216e6d40310511d3b5b5f6ecdeeeea52c37162", "score": 0.789894700050354, "title": "Pathophysiology, diagnosis, and management of endometriosis", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/0cbbf0daa0bb8ef217ba6cedb157341a9b6b5b65"}, {"rank": 3, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7930610775947571, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 4, "uid": "e5f5db4f8101f5f7285340b5b03a2db485fe299faac03665f4d6510c6f9b3c44", "score": 0.801950216293335, "title": "Nutrition in the prevention and treatment of endometriosis: A review", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/2656f9ca5ad760e53a69ca3c83b69e813c9d0f8a"}, {"rank": 5, "uid": "904fba66b63c455bcfd89f8336e6b11939cc1a59df5571baaf23ca17e835a254", "score": 0.8036229014396667, "title": "Compliance With Medical Treatment for Endometriosis : a Cross-sectional Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05619757"}, {"rank": 6, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.8120529651641846, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 7, "uid": "549fc5a0654dadfaafa376da2929f2d1c47787212b8791f0ed17ed77644daa13", "score": 0.8165602684020996, "title": "Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04844996"}, {"rank": 8, "uid": "7f5084b78b40bf222c9f668a617eeed2c7bf17f0467c805c22dbc16d258f6840", "score": 0.8226711750030518, "title": "Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT03778359"}], "query_id": 29}
{"ts_utc": "2025-11-20T00:05:41.619038+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states. Provide the response in a table. Cite the sources in the table", "top_k": 10, "used_faiss": true, "embed_endpoint": "https://boldwave-openai-dev.openai.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini-dev", "latency_ms": 7546, "usage": {"total_tokens": 2947}, "answer": "Here are the latest insights into treating endometriosis and their connections to other disease states, summarized in a table format:\n\n| Insight | Treatment Approach | Connection to Other Disease States | Source |\n|---------|-------------------|-----------------------------------|-------|\n| Hormonal treatments are the most common for managing endometriosis, focusing on blocking menstruation and hormonal suppression. | GnRH agonists and antagonists are effective in managing symptoms. | Hormonal treatments may also influence autoimmune and inflammatory conditions, as patients often have comorbidities like thyroiditis and arthritis. | [Hormonal treatments for endometriosis: The endocrine background](https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21) |\n| Nutritional interventions can reduce estrogen levels and inflammation, potentially alleviating symptoms. | Diets low in fat and high in fiber, along with plant-based diets, may be beneficial. | Dietary changes may also impact systemic inflammation and overall health, potentially benefiting conditions like obesity and metabolic syndrome. | [Nutrition in the prevention and treatment of endometriosis: A review](https://www.semanticscholar.org/paper/2656f9ca5ad760e53a69ca3c83b69e813c9d0f8a) |\n| Understanding the immune microenvironment is crucial for developing targeted therapies. | Research is focusing on the role of immune cells and cytokines in endometriosis pathogenesis. | Immune dysfunction in endometriosis may relate to other inflammatory diseases, highlighting a need for integrated treatment approaches. | [Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives](https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041) |\n| Targeting oxidative stress may provide new therapeutic avenues. | Treatments like N-acetylcysteine and curcumin are being explored for their antioxidant properties. | Oxidative stress is linked to various chronic diseases, including cardiovascular diseases and cancer, suggesting a broader relevance of these treatments. | [Targeting Oxidative Stress Involved in Endometriosis and Its Pain](https://www.semanticscholar.org/paper/f76db2e5cc1d38342b22c48a9666b1bc1cdd9cdf) |\n| New therapies, such as ezetimibe, are being investigated for their anti-inflammatory and antiangiogenic properties. | Ezetimibe has shown potential in reducing endometriotic tissue in experimental models. | This approach may also have implications for managing other conditions characterized by inflammation and angiogenesis, such as certain cancers. | [Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis](https://clinicaltrials.gov/study/NCT04844996) |\n\nThis table summarizes the current insights into endometriosis treatment and their potential connections to other health conditions, reflecting the multifaceted nature of the disease and its management.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.7734610438346863, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "e5f5db4f8101f5f7285340b5b03a2db485fe299faac03665f4d6510c6f9b3c44", "score": 0.7948036193847656, "title": "Nutrition in the prevention and treatment of endometriosis: A review", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/2656f9ca5ad760e53a69ca3c83b69e813c9d0f8a"}, {"rank": 3, "uid": "1b2aa8d886c9548b81b94cf1bb216e6d40310511d3b5b5f6ecdeeeea52c37162", "score": 0.8137351274490356, "title": "Pathophysiology, diagnosis, and management of endometriosis", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/0cbbf0daa0bb8ef217ba6cedb157341a9b6b5b65"}, {"rank": 4, "uid": "904fba66b63c455bcfd89f8336e6b11939cc1a59df5571baaf23ca17e835a254", "score": 0.826541006565094, "title": "Compliance With Medical Treatment for Endometriosis : a Cross-sectional Study", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT05619757"}, {"rank": 5, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.829612672328949, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 6, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.8298994898796082, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 7, "uid": "62eb58e0cab4e1efa110f5f4c1836c46db46f8e171cc72d2069c194594b9300c", "score": 0.832151472568512, "title": "Targeting Oxidative Stress Involved in Endometriosis and Its Pain", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/f76db2e5cc1d38342b22c48a9666b1bc1cdd9cdf"}, {"rank": 8, "uid": "549fc5a0654dadfaafa376da2929f2d1c47787212b8791f0ed17ed77644daa13", "score": 0.8409885168075562, "title": "Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04844996"}], "query_id": 30}
{"ts_utc": "2025-11-29T13:04:39.424235+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states.", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-5.1-chat", "latency_ms": 5300, "usage": {}, "answer": "Based on the provided context, here are the supported insights:\n\n• The latest therapeutic focus remains hormonal treatment, designed to suppress menstruation by inhibiting the hypothalamus‑pituitary‑ovary axis or inducing pseudodecidualization. GnRH agonists and antagonists are specifically mentioned as effective.\n\n• These treatments target the endocrine mechanisms driving the disease: estrogen‑dependency and progesterone‑resistance, which reduce apoptosis and increase oxidative stress, inflammation, and neuroangiogenesis.\n\n• Research highlights that endometriosis is a systemic disease with immune and endocrine involvement. Endometriotic cells express AMH, TGF‑related growth factors, CRH, and stress‑related peptides, which link the disease to broader systemic effects.\n\n• The immune microenvironment is increasingly recognized as central. Dysregulated macrophages, NK cells, DCs, neutrophils, and adaptive immune cells promote vascularization and fibrogenesis of lesions. Endocrine dysfunction further alters this immune environment.\n\n• These mechanisms tie endometriosis to other disease states: autoimmune disorders like thyroiditis and arthritis, allergic conditions, gastrointestinal and urinary inflammatory diseases, and mental health disorders.\n\n• Infertility is another major associated condition. Inflammation, altered pelvic anatomy, adhesions, ovarian dysfunction, and impaired endometrial receptivity all contribute. Treatment must be individualized because patient phenotypes vary widely.\n\nIf you want, I can summarize therapeutic directions only or expand on comorbidity links.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.691447913646698, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.7204762101173401, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 3, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7238163948059082, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 4, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.7319506406784058, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 5, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7340572476387024, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}], "query_id": 31}
{"ts_utc": "2025-11-29T13:05:15.389133+00:00", "question": "Yes please", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-5.1-chat", "latency_ms": 4683, "usage": {}, "answer": "I can provide only what is supported in the context:\n\n• The PEEPS clinical trial is a current therapeutic direction: an interdisciplinary, integrative group‑care program being tested to reduce endometriosis‑associated chronic pelvic pain. It focuses on pain interference, physical function, and quality of life.\n\n• A PubMed article asks whether cannabis should be used in endometriosis management, indicating that cannabis‑based therapy is an active area of investigation. The summary provides no details, so further specifics are uncertain.\n\n• \"Probing the pain\" suggests research attention on pain mechanisms, but the summary contains no usable details.\n\n• No other treatment insights are supported in the provided context.\n\nIf you want, I can outline only the research areas mentioned or note the gaps.", "docs": [{"rank": 1, "uid": "d38d3e3d2ba7554fef8cb05c4bf0880ad08bd097f952682f4f0bde2b60e954dc", "score": 1.5607341527938843, "title": "Author's Reply.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41057053/"}, {"rank": 2, "uid": "ae258701f1fa9d9a4dfb1e22fc9a996c8952220f2567813d5bba28e9d3cf87d6", "score": 1.6919522285461426, "title": "Should cannabis be used in the management of endometriosis?", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41070712/"}, {"rank": 3, "uid": "65be8e158331a40db9630b3854edf17faeccfe83a8e2df502fc08999500cd9e1", "score": 1.706028699874878, "title": "Probing the pain.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/40839730/"}, {"rank": 4, "uid": "6b65702083f23a3769363f44da1607a36299d9edc4a9bff1a9f2f71c625ab6ce", "score": 1.7106157541275024, "title": "The Christchurch point mutation in mouse APOE reduces Aβ-induced tau and α-synuclein pathologies", "source": "biorxiv", "url": "https://www.biorxiv.org/content/10.1101/2025.11.05.686857v1?rss=1"}, {"rank": 5, "uid": "fafb09272dea5b9261aec1ecad55d7b46ff6290442d15f4f00e9df4d1ddea1cc", "score": 1.712533712387085, "title": "Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain: the Peer Empowered Endometriosis Pain Support (PEEPS) Pilot Randomized Controlled Trial", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT06549985"}], "query_id": 32}
{"ts_utc": "2025-11-29T13:06:00.180245+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states.", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini", "latency_ms": 3132, "usage": {"total_tokens": 1289}, "answer": "The latest insights into treating endometriosis emphasize the use of hormonal treatments that target the endocrine aspects of the disease. These treatments aim to block menstruation by inhibiting the hypothalamus-pituitary-ovary axis or inducing a state of pseudodecidualization, which leads to amenorrhea and helps to impair the progression of endometriotic implants. GnRH agonists and antagonists are noted as effective options in this regard.\n\nAdditionally, endometriosis is recognized as a chronic systemic disease that can have systemic comorbidities, including autoimmune disorders (like thyroiditis and arthritis), inflammatory diseases (such as gastrointestinal and urinary conditions), and mental health issues. The interplay between endometriosis and these comorbidities is influenced by endocrine and inflammatory changes, which contribute to the pain and infertility often experienced by patients.\n\nFurthermore, the pathophysiology of endometriosis-associated infertility is complex and multifactorial, involving interactions between various factors such as pain, inflammation, altered pelvic anatomy, and disrupted ovarian function. This complexity necessitates individualized treatment approaches tailored to the specific clinical situation of each patient.\n\nOverall, the treatment of endometriosis is evolving, with a focus on understanding its systemic nature and the role of the immune microenvironment, which may offer new therapeutic perspectives.", "docs": [{"rank": 1, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.6914643049240112, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 2, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.7201107740402222, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 3, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7235174179077148, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 4, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.7316362857818604, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}, {"rank": 5, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7337683439254761, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}], "query_id": 33}
{"ts_utc": "2025-11-29T13:06:22.457489+00:00", "question": "Give it to me in a bullet fashion", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini", "latency_ms": 2058, "usage": {"total_tokens": 1050}, "answer": "- The U.S. FDA has published internal filing checklists to help determine if drug applications are complete and reviewable.\n- The FDA has launched a \"green list\" import alert to prevent illegal imported GLP-1 drug ingredients from entering the U.S. market.\n- HyperBind2 is a new multi-shot learning platform designed to improve antibody discovery through iterative lab-to-AI feedback cycles.\n- HyperBind2 can screen up to 100 million antibody candidates in 48 hours and improves model training accuracy from 65% to 85% across three rounds.\n- The platform requires minimal experimental data to converge on high-affinity antibodies, achieving a 21% success rate in validation by Round 3.", "docs": [{"rank": 1, "uid": "c1e343ba67c2ddf2325d42b52e6b84ec4477eb52f97082258e4fbfcc4bdd1c03", "score": 1.672288179397583, "title": "FDA Publishes Filing Checklists to Prevent Submission Delays", "source": "fda", "url": "http://www.fda.gov/news-events/press-announcements/fda-publishes-filing-checklists-prevent-submission-delays"}, {"rank": 2, "uid": "eb78858a40e60041bfc4f83bfefccf682434d573bde257ff9573d7088bbd4c91", "score": 1.6796646118164062, "title": "Top 10 priorities for future ectopic pregnancy research: an international consensus development study.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41022167/"}, {"rank": 3, "uid": "d38d3e3d2ba7554fef8cb05c4bf0880ad08bd097f952682f4f0bde2b60e954dc", "score": 1.684859037399292, "title": "Author's Reply.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41057053/"}, {"rank": 4, "uid": "5f1aa4fd100d7f3c6c3dc50ab6e0ef96d012e408b45dd12a99a25f3fa725c597", "score": 1.6891144514083862, "title": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients", "source": "fda", "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients"}, {"rank": 5, "uid": "fc819027c981fc806d3b2856fd1346c23eb70edbfb6a865bb39984441b54924b", "score": 1.6923574209213257, "title": "HyperBind2: Multi-Shot Learning Enables Progressive Improvement in Computational Antibody Discovery", "source": "biorxiv", "url": "https://www.biorxiv.org/content/10.1101/2025.11.06.687005v1?rss=1"}], "query_id": 34}
{"ts_utc": "2025-11-29T13:06:45.766108+00:00", "question": "I need this in a table", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini", "latency_ms": 5936, "usage": {"total_tokens": 1998}, "answer": "| Title                                                                 | Source        | URL                                                                                                   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n|-----------------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| A Phase 1, Randomised, Open-Label, Three-way, Three-period, Crossover Relative Bioavailability Study to Assess the Single-Dose Pharmacokinetics of FOR-6219 in Capsule and Tablet Formulations in Postmenopausal Women | ctgov         | [Link](https://clinicaltrials.gov/study/NCT04686669)                                                | This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the single-dose pharmacokinetics of FOR-6219 in capsule and tablet formulations in postmenopausal women. The effect of high-fat food on the pharmacokinetics of the tablet formulation will also be evaluated. A total of twelve, post-menopausal women, will be randomised to receive a single oral dose of FOR-6219 in three treatment periods: capsule formulation (fasted); tablet formulation (fed); tablet formulation (fasted). |\n| The Open Constellation of Nutritional Values: Mapping the Health Star Rating System | biorxiv       | [Link](https://www.biorxiv.org/content/10.1101/2025.11.05.686692v1?rss=1)                          | Nutritional awareness is increasing worldwide due to rising obesity rates and the widespread use of nutrition-tracking technologies. However, nutritional labels on food packaging remain difficult for many consumers to interpret. To improve clarity, public authorities have introduced simplified front-of-pack labeling systems, such as the Health Star Rating (HSR) used in Australia and New Zealand. The study introduces OpenHSR, the first open, FAIR-compliant dataset dedicated to the HSR system. |\n| HeraNorm: an R shiny application for identifying optimal endogenous controls for miRNA and RNA assays in qPCR and ddPCR. | pubmed        | [Link](https://pubmed.ncbi.nlm.nih.gov/41216219/)                                                  | [Summary not provided]                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| An open-source platform for reference data-driven analysis of untargeted metabolomics | biorxiv       | [Link](https://www.biorxiv.org/content/10.1101/2025.11.05.686710v1?rss=1)                          | Untargeted tandem mass spectrometry (MS/MS)-based metabolomics enables broad characterization of small molecules in complex samples. This study presents an open-source RDD metabolomics platform comprising a user-friendly web application and a Python software package that perform RDD analyses directly from molecular networking outputs generated by GNPS. The tools support visualization and statistical analysis of RDD results. |\n| Recall and Alert Resources                                            | fda           | [Link](http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/recall-and-alert-resources) | This page includes a list of various resources offered by the FDA regarding recalls and alerts for medical devices.                                                                                                                                                                                                                                                                                                                                                     |", "docs": [{"rank": 1, "uid": "ed05b2940325b524b5bd2d8b3fab5b8c6c17cfdba7ccd6e0054ea8af5030fecf", "score": 1.616353988647461, "title": "A Phase 1, Randomised, Open-Label, Three-way, Three-period, Crossover Relative Bioavailability Study to Assess the Single-Dose Pharmacokinetics of FOR-6219 in Capsule and Tablet Formulations in Postmenopausal Women", "source": "ctgov", "url": "https://clinicaltrials.gov/study/NCT04686669"}, {"rank": 2, "uid": "17be679064423aadaed80e7cc7ac3e4f907842f625d1485273411ef9ebd36632", "score": 1.6170763969421387, "title": "The Open Constellation of Nutritional Values: Mapping the Health Star Rating System", "source": "biorxiv", "url": "https://www.biorxiv.org/content/10.1101/2025.11.05.686692v1?rss=1"}, {"rank": 3, "uid": "f31aeba6b242fcc36148f337bae0727debce8502a57ad409a2c6de74ea3b820b", "score": 1.6317453384399414, "title": "HeraNorm: an R shiny application for identifying optimal endogenous controls for miRNA and RNA assays in qPCR and ddPCR.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41216219/"}, {"rank": 4, "uid": "1eebff97ec37b4e118d997703f6fffdfddf1aceb0633d9df1a739b20f2b5eb04", "score": 1.6406325101852417, "title": "An open-source platform for reference data-driven analysis of untargeted metabolomics", "source": "biorxiv", "url": "https://www.biorxiv.org/content/10.1101/2025.11.05.686710v1?rss=1"}, {"rank": 5, "uid": "ed2208eea8067747fb0fe244a3e9f78f8c21e64613c0f8636bca35320b05573e", "score": 1.641758918762207, "title": "Recall and Alert Resources", "source": "fda", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/recall-and-alert-resources"}], "query_id": 35}
{"ts_utc": "2025-11-29T16:57:29.496595+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-4o-mini", "latency_ms": 2834, "usage": {"total_tokens": 1336}, "answer": "Recent insights into treating endometriosis highlight its classification as a chronic systemic disease, which necessitates long-term management strategies. Hormonal treatments remain the most common approach, focusing on the endocrine aspects of the disease. Key mechanisms include estrogen-dependency and progesterone-resistance, which contribute to the ectopic implantation of endometrial cells, leading to increased inflammation, oxidative stress, and pain.\n\nThe treatment aims to inhibit menstruation through various means, such as GnRH agonists and antagonists, which can effectively manage symptoms by blocking the hypothalamus-pituitary-ovary axis or inducing a state of pseudodecidualization. This approach not only addresses the symptoms of endometriosis but also aims to mitigate associated infertility, which is a significant concern for many affected women.\n\nMoreover, endometriosis is linked to various systemic comorbidities, including autoimmune disorders, inflammatory diseases, and mental health issues. The interplay between endometriosis and these conditions suggests that the disease may have broader implications beyond reproductive health, affecting overall well-being. Understanding the molecular mechanisms underlying these associations could lead to more tailored and effective treatment strategies.\n\nInnovative diagnostic tools are being developed to better identify the specific dysfunctions in reproductive processes related to endometriosis, allowing for more personalized treatment plans. Overall, the latest insights emphasize the need for a comprehensive approach that considers the multifactorial nature of endometriosis and its impact on various aspects of health.", "docs": [{"rank": 1, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.6952551603317261, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 2, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.7002552151679993, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 3, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7306085824966431, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 4, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.736453652381897, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}, {"rank": 5, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.7367936372756958, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}], "query_id": 36}
{"ts_utc": "2025-11-29T16:58:04.456493+00:00", "question": "What are the latest insights with respect to treating endometriosis and how do they tie into other disease states", "top_k": 5, "used_faiss": true, "embed_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "embed_deployment": "text-embedding-3-large", "chat_endpoint": "https://jeffr-mhjmvbag-eastus2.cognitiveservices.azure.com/", "chat_deployment": "gpt-5.1-chat", "latency_ms": 7037, "usage": {}, "answer": "Here are the latest insights on treating endometriosis, based strictly on the provided context, and how they tie into other disease states:\n\n• Endometriosis is now viewed as a chronic systemic disease rather than only a gynecologic condition.  \n• Hormonal therapy remains the core medical treatment. It targets the endocrine mechanisms driving disease: estrogen‑dependency and progesterone‑resistance. These features promote ectopic endometrial cell survival, inflammation, oxidative stress, and neuroangiogenesis.  \n• Treatments such as GnRH agonists and antagonists work by suppressing the hypothalamus–pituitary–ovary axis or inducing pseudodecidualization to block menstruation and slow lesion progression.  \n\nHow these insights connect to other disease states:\n\n• The endocrine and inflammatory abnormalities in endometriosis are linked to systemic comorbidities. According to the provided context, these include:  \n  – autoimmune diseases (thyroiditis, arthritis, allergies)  \n  – inflammatory gastrointestinal and urinary diseases  \n  – mental health disorders  \n• Immune dysfunction, especially within the peritoneal microenvironment, plays a central role in the disease. Innate and adaptive immune cells (macrophages, NK cells, dendritic cells, neutrophils, T and B cells) and their cytokines contribute to lesion survival, vascularization, and fibrosis. These immune patterns overlap with mechanisms seen in other inflammatory and autoimmune conditions.  \n• Endometriosis also affects reproductive function through multiple pathways: inflammation, altered anatomy, adhesions, disrupted ovarian reserve, and compromised endometrial receptivity. This complexity resembles other multifactorial chronic diseases where systemic dysfunction affects organ‑specific outcomes.  \n• New non‑invasive diagnostics under development aim to identify specific dysfunctions in individual patients, enabling more tailored treatment—similar to personalized approaches used in other chronic inflammatory diseases.\n\nIn short, current insights emphasize endometriosis as a systemic endocrine‑immune‑inflammatory disorder, with treatments targeting hormonal suppression and growing interest in immune‑focused strategies. The systemic nature of the disease helps explain its overlap with autoimmune, inflammatory, and mental health conditions.", "docs": [{"rank": 1, "uid": "b2d007233a7c7a0281d6af319c874dc8529dbf68069e15b7069acbefdbb3ff5e", "score": 0.6952418088912964, "title": "Endometriosis is a chronic systemic disease: clinical challenges and novel innovations", "source": "openalex", "url": "https://doi.org/10.1016/s0140-6736(21)00389-5"}, {"rank": 2, "uid": "1c8ed8ba731a991421f868355b1c0d0d154f518417e6d235e85980049169a6cc", "score": 0.6998251676559448, "title": "Hormonal treatments for endometriosis: The endocrine background", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/885f40767e3c457e5ecbc326af5aa6355ccadc21"}, {"rank": 3, "uid": "ac111b981a92fa6f8d5d0d3d68c7608b2fade05c353c9f1cf5a06b1784cb9731", "score": 0.7304975986480713, "title": "Endometriosis-associated infertility: From pathophysiology to tailored treatment", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/a674e2370cdc471ae05a8c8e3cc41f4f788a633f"}, {"rank": 4, "uid": "f47a49c5d85a6c61c10f56537825bc97db8dd55dc6d46e076eda94b57563b993", "score": 0.7364428043365479, "title": "Endometriosis and comorbidities: molecular mechanisms and clinical implications.", "source": "pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/41038746/"}, {"rank": 5, "uid": "8387db7217c41689786d439129ad98855c8cda98c8752eb8d155443a5e5b9737", "score": 0.7367320656776428, "title": "Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives", "source": "semantic_scholar", "url": "https://www.semanticscholar.org/paper/4be4c6965a91912c11c6ca3cbae9a24bf6b81041"}], "query_id": 37}
